Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

0.9851 -0.0149 (-1.49%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phio Pharmaceuticals Corp. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

October 18, 2024

Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

October 18, 2024

Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

October 16, 2024

PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp....

Via Newsfile

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 10, 2024

Via Benzinga

PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024 ↗

May 09, 2024

Phio Pharma just reported results for the first quarter of 2024.

Via InvestorPlace

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

October 07, 2024

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp....

Via Newsfile

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

October 02, 2024

Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2,...

Via Newsfile

Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference

October 01, 2024

Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

September 25, 2024

Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

September 17, 2024

Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17,...

Via Newsfile

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

September 16, 2024

Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September...

Via Newsfile

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 09, 2024

Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp....

Via Newsfile

Topics Intellectual Property

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

August 29, 2024

Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

PHIO Stock Earnings: Phio Pharma Misses EPS for Q2 2024 ↗

August 14, 2024

PHIO stock results show that Phio Pharma missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

August 14, 2024

Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

August 06, 2024

Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Topics Intellectual Property

Phio Pharmaceuticals Announces New Chief Financial Officer

August 01, 2024

Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Topics Initial Public Offering

Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 29, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

July 29, 2024

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!

Via InvestorPlace

Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket ↗

July 29, 2024

Via Benzinga

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

July 12, 2024

Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company...

Via Newsfile

Topics Regulatory Compliance

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

July 08, 2024

Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8,...

Via Newsfile

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

July 05, 2024

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Phio Pharmaceuticals Announces Reverse Stock Split

July 02, 2024

Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company...

Via Newsfile

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

June 18, 2024

Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) -...

Via Newsfile

Topics Intellectual Property

Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying ↗

June 12, 2024

Via Benzinga

Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying ↗

June 11, 2024

Via Benzinga

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 28, 2024

Intratumoral PH-762 has encouraging safety profile in the initial cohortEscalation to proceed to next dose concentrationMarlborough, Massachusetts--(Newsfile Corp. - May...

Via Newsfile

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 23, 2024

Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...

Via Newsfile

Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update

May 09, 2024

From Phio Pharmaceuticals Corp.

Via GlobeNewswire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.